Scarica l'app Stockscreener
3.20
1.84%
-0.06
Dopo l'orario di chiusura:
3.16
-0.04
-1.25%
Dare Bioscience Inc Borsa (DARE) Ultime notizie
Brokers Offer Predictions for Daré Bioscience Q1 Earnings - Defense World
H.C. Wainwright maintains Buy rating on Dare Bioscience stock By Investing.com - Investing.com Canada
Daré Bioscience and Rosy Wellness Announce Strategic - GlobeNewswire
Daré Bioscience partners with Rosy Wellness for new women’s health cream - Investing.com
Dare Bioscience (DARE) Joins Forces with Rosy Wellness for Product Campaign | DARE Stock News - GuruFocus
Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream - Yahoo Finance
Dare Bioscience secures additional NIAID funding for HPV treatment - MSN
Q2 EPS Estimate for Daré Bioscience Increased by Analyst - Defense World
Daré outlines expanded dual path strategy targeting $4.5B hormone therapy market while accelerating commercialization in Q4 2025 - MSN
Daré Bioscience’s Earnings Call: Strategic Moves Amid Challenges - TipRanks
Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2025 Earnings Call Transcript - Insider Monkey
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates - MSN
Dare Bioscience Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Dare Bioscience (DARE) Expands Strategy to Enhance Value for Sta - GuruFocus
Dare Bioscience Inc (DARE) Q1 2025 Earnings Call Highlights: Strategic Expansions and Cost ... - Yahoo Finance
Daré Bioscience Expands Women’s Health Portfolio - TipRanks
Earnings call transcript: Dare Bioscience Q1 2025 unveils new products and cost cuts By Investing.com - Investing.com South Africa
Earnings call transcript: Dare Bioscience Q1 2025 unveils new products and cost cuts - Investing.com India
Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update - The Manila Times
Daré Bioscience Q1 2025 Financial Results and Company Update - TradingView
Daré Bioscience Unveils Major Commercial Push: 4 Women's Health Products Coming to $4.5B Market by 2026 - Stock Titan
Daré Bioscience (DARE) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq
Daré Bioscience, Inc. (NASDAQ:DARE) Shares Purchased by Renaissance Technologies LLC - Defense World
Daré Bioscience to Host First Quarter 2025 Financial - GlobeNewswire
Daré Bioscience Q1 Earnings: Women's Health Innovator to Share Latest Financial Results May 13 - Stock Titan
Geode Capital Management LLC Purchases 3,593 Shares of Daré Bioscience, Inc. (NASDAQ:DARE) - Defense World
Daré Bioscience targets Q4 2025 for Sildenafil Cream launch via 503B compounding - MSN
Daré Bioscience to Present at the Fierce Pharma Engage - GlobeNewswire
Daré CEO Unveils Game-Changing Women's Health Pipeline: Sildenafil Cream Launch Timeline Confirmed - Stock Titan
Daré Bioscience (NASDAQ:DARE) Share Price Crosses Below 200-Day Moving Average – Here’s What Happened - Defense World
Dare Bioscience granted extension by Nasdaq to regain compliance - Investing.com India
Daré Bioscience to Present at the Jones Healthcare and - GlobeNewswire
Daré's Game-Changing Strategy: Sildenafil Cream Heads to Prescription Market Earlier Than Expected - Stock Titan
Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year - GlobeNewswire
Daré Bioscience Q1 EPS Estimate Increased by HC Wainwright - Defense World
Q1 EPS Estimate for Daré Bioscience Decreased by Analyst - Defense World
HC Wainwright Forecasts Daré Bioscience FY2029 Earnings - Defense World
Short Interest in Daré Bioscience, Inc. (NASDAQ:DARE) Rises By 22.2% - Defense World
Daré Bioscience (NASDAQ:DARE) Receives Buy Rating from HC Wainwright - Defense World
Daré Bioscience Earnings Call: Strategic Progress Amid Challenges - TipRanks
Daré Bioscience (DARE) Anticipates Revenue Boost from Sildenafil Cream in 2025 - GuruFocus
Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2024 Earnings Call Transcript - Insider Monkey
Dare Bioscience Inc (DARE) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ... - Yahoo Home
Earnings call transcript: Dare Bioscience Q4 2024 focuses on women’s health innovations - Investing.com
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Dare Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Daré Bioscience Reports Full Year 2024 Financial Results - MarketScreener
DARE BIOSCIENCE Earnings Results: $DARE Reports Quarterly Earnings - Nasdaq
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update - TradingView
Daré Bioscience Reveals New Revenue Strategy: Sildenafil Cream Launch Coming Q4 2025 - Stock Titan
Daré Bioscience (NASDAQ:DARE) Stock Price Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Upcoming: Daré Bioscience Full Year Results Reveal Women's Health Innovation Progress - StockTitan
Daré Bioscience to Host Full Year 2024 Financial Results - GlobeNewswire
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):